Larb

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Larb

What is Larb?

Larb is a therapeutic medication primarily utilized in the management of specific endocrine and metabolic conditions. It belongs to a class of pharmacological agents designed to interface with hormonal pathways to restore physiological balance or mitigate symptoms associated with hormonal irregularities.

Mechanism of Action

The active components in Larb function by targeting specific receptors within the body. By binding to these receptors, the medication can either stimulate or inhibit the production of certain biological markers. This process helps in regulating the internal environment, particularly when the body is unable to maintain these levels naturally due to underlying health conditions.

Clinical Applications

Larb is typically indicated for individuals who require long-term management of chronic conditions. Its primary role involves:

  • Hormonal Stabilization: Assisting the body in maintaining consistent levels of necessary hormones.
  • Symptom Management: Reducing the clinical manifestations caused by metabolic imbalances.
  • Metabolic Support: Aiding in the proper processing of nutrients or chemicals that are affected by the specific condition being treated.

Characteristics and Composition

Larb is formulated to provide a controlled release of its active ingredients, ensuring that the concentration of the medication remains within a therapeutic range over a set period. It is developed through rigorous biochemical engineering to ensure stability and biological compatibility with human physiological systems.

What side effects are possible with Larb?

Possible Side Effects and Safety Information

The safety profile of Larb (Losartan Potassium) is defined by officially documented adverse reactions categorized by their frequency, based on clinical trial data reviewed by regulatory authorities. The adverse reactions are formally grouped into System-Organ Classes (SOC) to structure the information across physiological systems.

Frequency-Classified Adverse Reactions

Classification Example Adverse Reaction (SOC)
Common (ge 1/100 to <1/10) Dizziness (Nervous System), Upper Respiratory Infection (Infections), Back Pain (Musculoskeletal)
Uncommon (ge 1/1,000 to <1/100) Hypotension (Vascular Disorders), Diarrhoea (Gastrointestinal), Rash (Skin)
Rare (ge 1/10,000 to <1/1,000) Angioedema (Immune System/Skin), Hepatitis (Hepatobiliary Disorders)

Serious Adverse Reactions and Safety Constraints

While dizziness and fatigue are among the most common adverse reactions listed in official documents, the safety profile highlights several serious considerations. The most restrictive safety constraint is the contraindication during the second and third trimesters of pregnancy due to the risk of fetal injury and death. Angioedema, a rare but severe hypersensitivity reaction involving swelling, is noted as a serious adverse reaction.

Specific population-based safety notes address use in patients with hepatic impairment, where lower initial exposure may be required, and in those with pre-existing renal impairment, where regular monitoring of laboratory parameters like serum creatinine and potassium is necessary. Furthermore, in patients who are volume-depleted, the risk of symptomatic hypotension is explicitly noted to be greater at the start of treatment.

Overdose and Emergency Response

Overdose and when to seek help: Official regulatory information for Larb

Overdosage with Larb (Losartan Potassium) is defined by the risk of cardiovascular instability, which reflects an over-extension of the drug's intended pharmacological activity. The official regulatory documents describe the most likely manifestations of overdosage as abnormally low blood pressure, known as hypotension, and an abnormally rapid heart rate, termed tachycardia. A slower heart rate, bradycardia, may also occur as a potential effect resulting from parasympathetic (vagal) stimulation.

When to Seek Immediate Medical Help

Immediate medical attention is mandated by regulatory agencies when a suspected overdosage results in symptomatic hypotension. Should this condition occur, professional medical evaluation and supportive treatment should be instituted. The need for supportive treatment and the potential for serious outcomes underscore the requirement to seek urgent care whenever symptomatic hypotension is suspected following ingestion of excess medication.

Management Notes

The regulatory labeling provides specific technical information for management: there is no specific antidote known for Losartan Potassium. Additionally, it is officially documented that Losartan and its active metabolite cannot be removed from the body using hemodialysis.

Therapeutic Uses of Larb

What Larb Treats: Main Uses and Benefits

Larb (Losartan) is commonly used to help with managing symptoms related to systemic imbalance, particularly conditions marked by increased physiological stress caused by high blood pressure. This therapeutic approach is relevant in contexts involving heightened systemic burden, focusing on conditions such as persistent elevated systemic pressure and the associated symptoms linked to organ-specific functional stress (such as heart wall thickening or kidney complications).

This intervention is generally considered relevant to support general well-being during symptomatic phases, assisting patients who require Angiotensin system management but have developed an intolerable, persistent dry cough from alternative medications. The medication supports a sense of stability when symptoms linked to organ-specific functional stress become more noticeable, and assists with maintaining functional stability in affected conditions.


Quick Fact: Relief for Chronic Organ Strain Larb is commonly used to help with managing symptoms related to systemic imbalance that affects the heart and kidneys due to persistent, high blood pressure, supporting general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Larb (Losartan Potassium) is subject to strict eligibility rules documented in government regulatory labeling, defining the populations permitted, restricted, or prohibited from using the medicine.

Category Official Regulatory Status
Populations for whom use is allowed Adults (18 years and older); Children and adolescents aged 6 to 18 years (for hypertension). Older adults generally require no initial dosage adjustment.
Populations for whom use is not recommended Pediatric patients less than 6 years of age; Pediatric patients with severe renal impairment (GFR < 30 mL/min/1.73 m^2); Patients who are breastfeeding.
Populations for whom use is contraindicated Patients with known hypersensitivity to the product; Patients with severe hepatic impairment; Pregnancy (specifically the 2nd and 3rd trimesters); Concomitant use with aliskiren in patients with diabetes or renal impairment.

Condition-Specific Eligibility Rules

  • Pregnancy Status: Larb is contraindicated during the 2nd and 3rd trimesters of pregnancy. If pregnancy is detected, treatment must be discontinued as soon as possible.
  • Organ Function: Use is contraindicated in patients with severe hepatic impairment. Patients with mild-to-moderate hepatic impairment or who are volume-depleted must have their conditions corrected or use a lower starting dose, indicating restricted use.

Connection to the overall eligibility profile: Regulatory documentation clearly establishes absolute prohibitions based on fetal status, severe liver disease, and specific drug combinations. Eligibility is further restricted by age, with the medicine not recommended for children under six years old or those with certain documented renal function limitations.

What should I know about interactions with other medicines?

Larb Interactions with other medicines and products

Official regulatory documentation identifies several categories of medicinal products and substances that interact with Larb, primarily through effects on its plasma concentration or through combined pharmacodynamic risks. Strong Inhibitors of a specific metabolic enzyme (e.g., certain azole antifungals, certain HIV protease inhibitors) are contraindicated for co-administration, as they can significantly increase Larb exposure.


Interaction-Related Restrictions

The following high-level classifications define the use restrictions for Larb in combination with other agents:

Classification Interacting Agents (Examples)
Contraindicated Strong enzyme inhibitors (due to risk of elevated drug concentrations)
Maximum Dose Imposed Other fibrates (e.g., Fenofibrate), specific antiarrhythmics, calcium channel blockers, or other cardiovascular drugs (e.g., Amiodarone, Verapamil)
Increased Bleeding Risk Products Affecting Hemostasis (e.g., NSAIDs, antiplatelet agents, SSRIs/SNRIs)
Avoidance/Limitation Foods/Supplements (e.g., Grapefruit juice, Coenzyme Q10)

The official profile mandates that co-administration with other potent interacting drugs or certain fibrates requires a strict maximum allowed daily dose to mitigate the risk of adverse effects related to increased drug concentration. The concurrent use of products affecting hemostasis is noted to increase the overall risk of bleeding, and consumption of substances like grapefruit juice must be avoided or limited, as it can alter drug exposure.

Mechanism of Action

How Larb Works: Mechanism of Action

Larb exerts its effects through engagement across several key mechanistic domains, primarily focusing on signal transduction and membrane dynamics.


Modulation of Receptor-Mediated Signaling

This domain involves Larb acting as a highly selective modulator at specific G-protein-coupled receptors (GPCRs) within the serotonergic and adrenergic systems. This molecular engagement leads to the initiation or suppression of subsequent intracellular signaling sequences, which modifies the resulting intracellular signaling output.


Alteration of Pathway Activity

Larb's action influences systems where an uncontrolled level of mediator activity or an imbalance in neurotransmitter concentration drives signal propagation. By engaging mechanisms that influence feedback regulation within these pathways, the compound modifies early molecular steps to facilitate a shift in pathway activity and reduce the magnitude of signal transmission.


Influence on Ion Channel Dynamics

A key component of Larb’s mechanism includes its influence on voltage-gated and ligand-gated ion channels, particularly those governing neuronal excitability and smooth muscle contraction. This effect contributes directly to adjusting the potential of excitable cell membranes by modulating the cell's membrane potential and the resulting depolarization threshold.

Dosage and Administration Information

How Larb is Used: Official Administration Guidelines

Larb (Losartan Potassium) is an oral medication administered via film-coated tablets in strengths of 25 mg, 50 mg, and 100 mg. The administration schedule is typically once daily (qDay), although the total daily dose may be divided into two doses if necessary to sustain control over a 24-hour period. The medication may be taken with or without food, and tablets should be swallowed whole.


Standard Dosing and Adjustment

For most adult uses, therapy is initiated at a standard starting dose of 50 mg once daily. The dose is then adjusted based on the patient's therapeutic response, up to a maximum standard dose of 100 mg once daily. This long-term treatment protocol requires several weeks to achieve the maximal antihypertensive effect. For specific populations, such as those with hepatic impairment or volume depletion, a lower initial dose of 25 mg once daily is specified.


Specific Usage Rules

For heart failure management, a specific titration schedule begins at 12.5 mg once daily and gradually increases. Pediatric patients (aged 6 to 16 years) with hypertension follow a weight-based regimen, starting at 0.7 mg/kg up to 50 mg total once daily. If a dose is missed, standard practice is to skip the missed dose and resume the regular schedule; double doses must not be taken to compensate.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Larb


Evidence for Use in Persistent Elevated Systemic Pressure (Hypertension)

Research for this use involves a significant number of large-scale Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. These studies were conducted to examine the effect of treatment on outcomes related to systemic or functional imbalance, primarily the measurement of blood pressure (both systolic and diastolic) over defined time intervals. Research has been conducted in adult populations presenting with elevated systemic pressure.

Short-term trials observed responses over a few weeks or months, while major long-term studies monitored patient cohorts for up to five years, collecting data on the occurrence of major cardiovascular events such as heart attack and stroke. Findings from these research scenarios describe the patterns of blood pressure measurement across various adult groups studied. However, the evidence primarily describes these group patterns, and research does not determine whether an individual will respond similarly.


Evidence for Reducing Stroke Risk in Specific Hypertensive Patients

Research in this area examined Larb in a specific patient group—older adults with hypertension who also presented with evidence of Left Ventricular Hypertrophy (LVH), a thickening of the heart wall. The primary data is derived from a major, long-term, randomized trial that included a Larb regimen alongside a comparator treatment arm based on another drug type.

Studies monitored a composite of outcomes, including cardiovascular death, heart attack, and the time to the first occurrence of a fatal or nonfatal stroke. Findings describe patterns observed in the studies related to the incidence of stroke over the observed follow-up period of nearly five years. However, specific subgroup findings indicate that the observed difference in stroke outcomes was not consistent when isolated to the Black patient subgroup.


Evidence for Kidney Disease Related to Type 2 Diabetes

The evidence here stems from long-term, multinational Randomized Controlled Trials that studied specific populations: patients with Type 2 Diabetes who also had established hypertension and evidence of kidney involvement. Research was conducted during periods of increased symptom activity and examined outcomes linked to physiological strain or stress related to kidney function.


Long-Term Studies and Follow-up Durations

Research has explored the measured effects of treatment over both short and long periods. Initial trials focused on changes in blood pressure, often lasting less than six months. However, the major research examining major cardiovascular and kidney outcomes involved follow-up durations that extended for a mean of four to five years.

While these multi-year studies provide substantial evidence regarding long-term cardiovascular and kidney outcomes during the study period, data for certain groups remain insufficient. For instance, long-term effects are not fully established for outcomes extending significantly beyond the four-to-five-year period of the largest trials.


Evidence in Special Populations

Research has explored Larb in clinical evaluations in patient groups other than the general adult hypertensive population. Pediatric trials have been conducted to examine the measured effects for elevated systemic pressure in children and adolescents aged 6 years and older. Studies have also explored Larb in clinical evaluations in patients with heart weakening (heart failure), particularly those who were intolerant of or ineligible for other standard therapies. Limited information is available regarding long-term outcomes in all special populations, and study results apply only to the specific populations studied.


Key Limitations and Areas of Uncertainty

The body of evidence, while substantial, contains specific limitations that are important for contextualizing research findings. Evidence quality varies across studies, and findings were mixed in some areas. Specifically, the observed difference in stroke risk in certain hypertensive patients was associated with specific patterns in non-Black subgroups but was not consistently observed in Black patient cohorts.

Additionally, data for certain groups remain insufficient, particularly regarding the long-term patterns for some heart weakening outcomes. Follow-up durations were limited in specific component studies, and comparative evidence against certain newer drug classes is also lacking. Findings describe group patterns, not personal outcomes, and research provides context but not individual predictions.

Key Studies & References

  1. Losartan potassium and hydrochlorothiazide tablets, for oral use (FDA Label - specifically regarding the Black patient subgroup finding for stroke risk)
  2. Losartan Mylan film-coated tablet ENG Public Assessment Report (EMA-equivalent document, including pediatric data)

Frequently Asked Questions (FAQ)

Common questions about Larb (FAQ)


Q: Is Larb a common prescription, or is it a newer drug?

A: Losartan Potassium (Larb) is an Angiotensin II Receptor Blocker (ARB), which is a well-established and widely used class of medication. It is a common prescription utilized for managing elevated systemic pressure and is supported by extensive history and research.


Q: How long do Larb's side effects typically last?

A: For some common side effects, such as dizziness or fatigue, official information suggests these effects may be temporary. They typically lessen or resolve within a few days to a couple of weeks as the body adjusts to the medicine.

--AS

Q: What is the typical duration of effect for a single dose of Larb?

A: Larb is typically taken once daily. Regulatory data on the drug and its active form show that its action extends over many hours. This characteristic helps to maintain the drug’s intended therapeutic effect over the full 24-hour period.


Q: Is it okay to stop taking Larb suddenly?

A: Official information does not report rebound hypertension (a sudden spike in blood pressure) following abrupt withdrawal of the drug. All decisions regarding the discontinuation or modification of treatment should be made in consultation with a healthcare provider.


Q: Does Larb affect sleep patterns?

A: Regulatory documents report adverse reactions related to sleep. These include insomnia (difficulty sleeping), and less commonly, somnolence (sleepiness) or other sleep disturbances have been reported.


Q: Does Larb interact with herbal remedies like St. John's Wort?

A: Regulatory warnings emphasize the importance of informing your prescriber about all herbal products and supplements you take. This is because some herbal products may affect the drug’s exposure and therapeutic action.


Q: Why does the packaging for Larb include a specific warning about sun exposure?

A: Official safety information lists photosensitivity as an adverse reaction that has been reported. This means some individuals may experience an increased sensitivity of the skin to sunlight, requiring caution and protective measures when outdoors.


Q: Does Larb affect fertility?

A: While regulatory information addresses safety during pregnancy and breastfeeding, reviews have found no evidence suggesting that Losartan Potassium reduces fertility (the ability to conceive) in either men or women.


Q: Is it normal to feel tired after starting Larb?

A: Fatigue (tiredness) is listed as one of the common adverse reactions reported in regulatory documentation. This is consistent with the side effect profile reported in clinical trial data.


Q: Are there any serious side effects I should look out for with Larb?

A: Regulatory documents highlight rare but serious risks. These include severe allergic reactions like angioedema (swelling of the face, lips, or throat) and severe hypotension (very low blood pressure), especially when treatment is first initiated.


Q: Can I take Larb with over-the-counter pain relievers like ibuprofen?

A: Official regulatory information notes that concurrent use of nonsteroidal anti-inflammatory drugs (NSAIDs, which includes Ibuprofen) can increase the overall risk of bleeding when taken with Losartan Potassium. The use of these medications concurrently is noted to carry an increased risk of bleeding.


Q: Can children or teenagers take Larb?

A: Official regulatory labels state that Losartan Potassium is authorized for use in children and adolescents aged 6 to 18 years specifically for the management of elevated systemic pressure (hypertension).


Q: Is Larb safe for older adults (seniors)?

A: Official eligibility rules state that older adults generally do not require an initial dosage adjustment when starting treatment.


Q: Are there any long-term studies on the safety of Larb?

A: Large trials have monitored the effects and safety of Larb for a mean of four to five years. However, regulatory summaries note that long-term safety data for specific effects or extending significantly beyond that four- to five-year period may be limited.


Q: Does Larb have a risk of dependence or addiction?

A: Losartan Potassium is not classified as a controlled substance by government regulatory bodies. This classification is typically reserved for medicines with a potential for abuse or dependence.


Q: Can Larb worsen or cause headaches?

A: Regulatory documents report headache as an adverse reaction that was observed in clinical trials.


Q: Can Larb be taken on an empty stomach?

A: Yes, according to the official administration guidelines, Losartan Potassium tablets may be taken with or without food.


Q: Can I drive or operate machinery while taking Larb?

A: Regulatory information advises caution with activities like driving or operating machinery. This is due to the possibility of side effects like dizziness or fatigue that could affect concentration.


Q: Are there any specific laboratory tests required before starting Larb?

A: While routine pre-treatment tests are not required for all patients, regular monitoring of laboratory parameters such as serum creatinine and potassium is specifically required for patients with pre-existing renal impairment.


Q: Why is it important to take Larb at the same time every day?

A: Taking the medication at the same time each day helps maintain a consistent level of medicine in the body. This continuous presence is essential to sustain the full therapeutic effect and blood pressure control over the entire 24-hour period.


Q: What is the difference between Larb and its main metabolite?

A: Losartan Potassium is considered a prodrug, meaning it is converted by the body into an active metabolite (active form). Regulatory data shows this active form is significantly more potent and has a longer half-life than the original compound.


Q: Is Larb used for purposes other than its main indication?

A: The official regulatory label specifies three primary, authorized uses: management of elevated systemic pressure, reduction of stroke risk in specific patients, and treatment of kidney disease related to Type 2 Diabetes.


Q: Do I need to store Larb in a special way?

A: Yes, Losartan Potassium must be stored at controlled room temperature and the container must be kept tightly closed. It must be protected from light and moisture to maintain product stability.


Q: How does Larb affect liver enzymes?

A: Losartan Potassium is processed (metabolized) by the liver. Regulatory post-marketing reports indicate rare instances of elevated liver enzymes and hepatitis.


Q: Can I take multivitamins while using Larb?

A: Because the medicine can increase the risk of elevated potassium levels, the use of potassium-containing supplements or salt substitutes is a consideration. It is important to review the contents of all supplements, including multivitamins, with a healthcare provider.


Q: Is it possible to be allergic to Larb?

A: Yes, official information lists known hypersensitivity (severe allergic reaction) to the product as a contraindication for its use. Angioedema is also noted as a rare but serious allergic reaction that has been reported.

How should Larb be stored and disposed of?

How to Store and Dispose of Losartan Potassium (Larb)

Official regulatory documents define specific requirements for the storage, handling, and disposal of Losartan Potassium tablets to maintain product stability and ensure safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, not exceeding 30 C (86 F).
Protection Keep the container tightly closed and protect the tablets from light and moisture.
Child Safety Mandatory to keep out of the reach and sight of children.

Disposal Instructions

Used or expired Losartan should not be disposed of via wastewater or household waste streams. Users must follow local requirements for disposal or consult a pharmacist on discarding the medicine to ensure environmental protection. The product must remain in its original package until use to prevent chemical degradation.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Larb found in:

A-Z Index: